An observational study in COVID, Acute Coronary Syndrome and Myocardial Infarction, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 8 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Centre Hospitalier Universitaire de Nice · Observational
Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
739 studies on the registry are indexed under Pulmonary Embolism; 159 are open to participants now.
This study's enrollment of 198 is below the median of 392 across 324 observational studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Intensive care unit, hospital ward
Exclusion Criteria:
Patients presenting with cardiomyopathies or venous thromboembolism
Patients without cardiomyopathies or venous thromboembolism
Patients admitted in intensive care unit
Patients admitted in hospital ward
Determine the incidence of cardiomyopathies and venous thromboembolism
Incidence of cardiomyopathies and/or venous thromboembolism at day 28
Time frame: 28 days
Mortality
Incidence of mortality at day 28
Time frame: 28 days
Duration of mechanical ventilation
Number of day of using mechanical ventilation for each patients
Time frame: hospitalisation duration
Shock
Incidence of shock during hospitalisation
Time frame: hospitalisation duration
length of stay
Number of day at hospital
Time frame: hospitalisation duration
Mechanical ventilation
Setting up or not of mechanical ventilation
Time frame: hospitalisation duration
Renal replacement therapy
Administration or not of renal replacement therapy
Time frame: hospitalisation duration
Plan to share: No — no data sharing plan has been established.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice